Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

57.00 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
89 90 Next >
News headline image
Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout ↗
Cobenfy is the first drug to treat the disorder without blocking dopamine. 
Via Investor's Business Daily
News headline image
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients ↗
The FDA's advisory committee is set to evaluate the use of PD-1 inhibitors in gastric cancer patients, focusing on the risks and benefits for those with varying PD-L1 levels, including low expressers. 
Via Benzinga
News headline image
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability ↗
2seventy bio halts enrollment in its KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company expects strong growth following FDA approval... 
Via Benzinga
News headline image
Analysts Think There's Still Time to Get in on Edgewise, Up 332%
Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run? 
Via MarketBeat
News headline image
NYSE:BMY Shows Potential for a Breakout. ↗
A technical analysis of BRISTOL-MYERS SQUIBB CO (NYSE:BMY) shows it may be setting up for a breakout. 
Via Chartmill
News headline image
What Analysts Are Saying About Bristol-Myers Squibb Stock ↗
 
Via Benzinga
News headline image
Current Report: Bristol-Meyers Squibb (BMY) ↗
The most recent $0.60 Q dividend was declared September 10th for shareholders of record October 4th and is payable November 1st. There’s time to fetch this payout! 
Via Talk Markets
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years ↗
KarXT, a novel schizophrenia drug, is on the verge of FDA approval, promising to revolutionize treatment. However, access challenges within the US healthcare system could limit its impact on mental... 
Via Benzinga
News headline image
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip ↗
Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb, just behind Cytokinetics. 
Via Investor's Business Daily
News headline image
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. 
Via Investor's Business Daily
News headline image
Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy ↗
Bristol Myers Squibb announces Phase 3 DAYBREAK trial data showing Zeposia (ozanimod) reduces brain volume loss in relapsing multiple sclerosis patients. 
Via Benzinga
News headline image
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
From Bristol Myers Squibb
Via Business Wire
News headline image
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade ↗
Now could be a great time to scoop up three stocks trading way below their previous peaks. 
Via The Motley Fool
News headline image
Merck Scores Two Key Victories With Keytruda In Women's Cancers ↗
The company also unveiled 10-year test results for Keytruda in advanced melanoma patients. 
Via Investor's Business Daily
News headline image
Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced Melanoma
From Bristol Myers Squibb
Via Business Wire
News headline image
Got $200? 2 Healthcare Stocks to Buy and Hold Forever ↗
These two stocks have had their issues in recent years, but both look like reliable long-term bets. 
Via The Motley Fool
News headline image
Time To Invest And Or Trade In Bio-Tech Stocks? ↗
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
News headline image
Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
News headline image
Bernie Sanders Says If You're Poor In America You'll Live 10-15 Years Less: 'Anybody Else See A Problem With That?' ↗
 
Via Benzinga
News headline image
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst ↗
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... 
Via Benzinga
News headline image
Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
From Bristol Myers Squibb
Via Business Wire
News headline image
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100 ↗
These dividend payers could more than double their payouts in the decade ahead. 
Via The Motley Fool
News headline image
FDA Battles Backlog of Drug Factory Inspections Since COVID-19 ↗
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked. 
Via Benzinga
News headline image
Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
From Bristol Myers Squibb
Via Business Wire
News headline image
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs ↗
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... 
Via Benzinga
Topics Economy
News headline image
2 Reasons Bristol Myers Squibb Stock Could Be a Bargain, Down 34% From Its All-Time High ↗
Rebounding growth could make shares of this leading drugmaker a big winner. 
Via The Motley Fool
News headline image
2 No-Brainer Large-Cap Stocks to Buy With $500 Right Now ↗
No stock is perfect, but quality businesses can stand the test of time in your portfolio. 
Via The Motley Fool
News headline image
Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
89 90 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.